Delving into the Latest Updates on Guangzhou Koncen Bioscience Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Nervous System Diseases

Respiratory Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	4
Nervous System Diseases	3
Infectious Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	6
Chemical drugs	1

Top 5 Target	Count

autotaxin(Ectonucleotide pyrophosphatase/phosphodiesterase 2)	2
neuraminidase	1

主要目的剂量递增试验：评估HNC664胶囊单药在晚期实体瘤患者中的安全性和耐受性，观察剂量限制性毒性（DLT），确定HNC664最大耐受剂量（MTD）和扩展试验推荐剂量，为后续临床试验给药剂量和给药方案提供依据。扩展试验：评价HNC664胶囊联合吉西他滨和白蛋白紫杉醇在局部晚期或转移性胰腺癌患者中的安全性及初步疗效。次要目的：评价HNC664胶囊单药或与吉西他滨和白蛋白紫杉醇联用在晚期实体瘤患者中的药代动力学（PK）和药效动力学（PD）特征；探索性目的（仅扩展试验）：探索胰腺癌患者血液中的生物标志物与疗效之间的关系。

[Translation]

Main purpose Dose escalation trial: Evaluate the safety and tolerability of HNC664 capsules alone in patients with advanced solid tumors, observe dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) of HNC664 and the recommended dose for the extended trial, and provide a basis for the subsequent clinical trial dosage and dosing regimen. Extended trial: Evaluate the safety and preliminary efficacy of HNC664 capsules combined with gemcitabine and albumin-paclitaxel in patients with locally advanced or metastatic pancreatic cancer. Secondary purpose: Evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of HNC664 capsules alone or in combination with gemcitabine and albumin-paclitaxel in patients with advanced solid tumors; Exploratory purpose (extended trial only): Explore the relationship between biomarkers in the blood of pancreatic cancer patients and efficacy.

Start Date27 Oct 2022

Sponsor / Collaborator

Guangzhou Koncen Bioscience Co., Ltd.

NCT04504448 / CompletedPhase 1

A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Doses (SAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of HNC664

The purpose of this First-in-Human study is to evaluate the safety , tolerability，PK and PD after single ascending of HNC664 given to healthy subjects, compared to placebo. Also, food effect will be evaluated.

Start Date11 Aug 2020

Sponsor / Collaborator

Guangzhou Koncen Bioscience Co., Ltd.

100 Clinical Results associated with Guangzhou Koncen Bioscience Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Koncen Bioscience Co., Ltd.

Login to view more data

4

Literatures (Medical) associated with Guangzhou Koncen Bioscience Co., Ltd.

01 Mar 2018·Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

[Eukaryotic expression, purification of human IgECepsilon2-4 protein and its target fishing].

Article

Author: Wang, Ping ; Li, Zhen ; Dong, Wenqi ; Huang, Huihui ; Wang, Zheyan ; Yang, Zhenggen

Objective To construct eukaryotic expression vectors of human IgE heavy chain 2-4 region (IgECepsilon2-4) and purify the recombinant protein, and then capture its interacted proteins by surface plasmon resonance (SPR). Methods Three recombinant eukaryotic expression vectors of IgECepsilon2-4 containing different signal peptides were constructed and transiently transfected into HEK293FT suspension cells separately. The recombinant plasmid with the highest-level expression was selected to express the recombinant protein in a huge amount, and then the recombinant protein was purified by Ni-NTA affinity chromatography. The interaction between high-affinity IgE receptor (FcepsilonR I) of KU812 cell surface and IgECepsilon2-4 was identified by immunofluorescence cytochemistry. The unknown proteins that specifically interacted with IgECepsilon2-4 were captured from human serum by SPR technique. Results The recombinant plasmid containing the signal peptide III showed the highest expression (6.2 mg/L). Highly purified recombinant protein IgECepsilon2-4 was obtained by affinity purification. Immunofluorescence cytochemistry showed that the recombinant protein IgECepsilon2-4 could be combined with the surface receptor of KU812 cells. Thirty-nine kinds of proteins which were likely to interact with IgECepsilon2-4 were captured from human serum by SPR. Conclusion We obtained the purified recombinant protein IgECepsilon2-4 that could be combined with KU812 cell surface receptor. Target fishing experiment revealed that the recombinant protein IgECepsilon2-4 was likely to interact with 39 kinds of proteins in human serum.

Chinese journal of cellular and molecular immunology

[Eukaryotic expression, purification of human IgECepsilon2-4 protein and its target fishing].

Author: Huihui Huang ; Zhen Li ; Zhenggen Yang ; Zheyan Wang ; Ping Wang ; Wenqi Dong

Objective To construct eukaryotic expression vectors of human IgE heavy chain 2-4 region (IgECepsilon2-4) and purify the recombinant protein, and then capture its interacted proteins by surface plasmon resonance (SPR). Methods Three recombinant eukaryotic expression vectors of IgECepsilon2-4 containing different signal peptides were constructed and transiently transfected into HEK293FT suspension cells separately. The recombinant plasmid with the highest-level expression was selected to express the recombinant protein in a huge amount, and then the recombinant protein was purified by Ni-NTA affinity chromatography. The interaction between high-affinity IgE receptor (FcepsilonR I) of KU812 cell surface and IgECepsilon2-4 was identified by immunofluorescence cytochemistry. The unknown proteins that specifically interacted with IgECepsilon2-4 were captured from human serum by SPR technique. Results The recombinant plasmid containing the signal peptide III showed the highest expression (6.2 mg/L). Highly purified recombinant protein IgECepsilon2-4 was obtained by affinity purification. Immunofluorescence cytochemistry showed that the recombinant protein IgECepsilon2-4 could be combined with the surface receptor of KU812 cells. Thirty-nine kinds of proteins which were likely to interact with IgECepsilon2-4 were captured from human serum by SPR. Conclusion We obtained the purified recombinant protein IgECepsilon2-4 that could be combined with KU812 cell surface receptor. Target fishing experiment revealed that the recombinant protein IgECepsilon2-4 was likely to interact with 39 kinds of proteins in human serum.

Molecular Medicine ReportsQ4 · MEDICINE

Bioinformatics analysis of differentially expressed proteins in alcoholic fatty liver disease treated with recombinant human cytoglobin

Q4 · MEDICINE

Article

Author: Xu, Yan-Mei ; Dong, Wen-Qi ; Wen, Jian ; Chen, Bo-Hong ; Wei, Wei ; Yang, Zheng-Gen ; Wang, Ping ; Li, Zhen ; Wang, Zhe-Yan ; Zhang, Zi-Rong

Cytoglobin (Cygb) is a globin molecule that is ubiquitously expressed in all tissues and has a protective role under oxidative stress. It has also been demonstrated to be effective in the treatment of alcoholic fatty liver disease (AFLD). In order to study the molecular mechanisms underlying its beneficial effects for the treatment of alcoholic liver, two‑dimensional electrophoresis and mass spectrometric analysis were performed on serum and liver tissues from an in vivo rat model of AFLD. A total of 26 differentially expressed proteins were identified in the serum and 20 differentially expressed proteins were identified in liver specimens. Using online bioinformatics tools, it was indicated that these differentially expressed proteins were primarily associated with pathways including binding and uptake of ligands by scavenger receptors, response to corticosteroid, plasma lipoprotein remodeling, regulation of complement cascade, hydrogen peroxide catabolic process, as well as response to nutrient and monosaccharide. The present results suggested that recombinant human Cygb exerts its role in the treatment of AFLD primarily through affecting nutrient metabolism, monocarboxylic acid biosynthesis, regulation of glutathione expression, plasma lipoprotein remodeling and removal of metabolic waste from the blood.

100 Deals associated with Guangzhou Koncen Bioscience Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Koncen Bioscience Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

IND Application

Phase 1 Clinical

2

1

Phase 2 Clinical

Other

7

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HNC-042 ( neuraminidase )	Influenza, Human More	Phase 2
HNC664 ( autotaxin )	Pancreatic Cancer More	Phase 1
HNC1058 ( autotaxin )	Idiopathic Pulmonary Fibrosis More	Phase 1
HNC364	Parkinson Disease More	IND Application
HNC-1798	Parkinson Disease More	Preclinical